Insider Buying: Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Purchases $49,983.22 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Michael Houghton bought 3,202 shares of Assembly Biosciences stock in a transaction dated Monday, December 30th. The shares were bought at an average cost of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the transaction, the director now owns 3,202 shares of the company’s stock, valued at approximately $49,983.22. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Assembly Biosciences Trading Up 8.7 %

NASDAQ ASMB opened at $17.15 on Friday. The firm’s 50 day moving average price is $16.01 and its 200-day moving average price is $15.61. Assembly Biosciences, Inc. has a 52-week low of $9.12 and a 52-week high of $19.93.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ASMB shares. Jefferies Financial Group upgraded Assembly Biosciences from a “hold” rating to a “buy” rating and raised their price objective for the stock from $2.00 to $35.00 in a report on Friday, September 20th. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a report on Friday, December 27th.

Institutional Trading of Assembly Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. JPMorgan Chase & Co. lifted its stake in shares of Assembly Biosciences by 5,137.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 3,442 shares during the last quarter. FMR LLC raised its holdings in Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 3,635 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Assembly Biosciences by 131.0% during the second quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock valued at $184,000 after buying an additional 7,690 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Assembly Biosciences by 39.2% in the 2nd quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after buying an additional 15,451 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in shares of Assembly Biosciences in the 2nd quarter worth approximately $6,421,000. Institutional investors own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.